• Phil Taylor
• 29 Jan, 2019

The green light from the US regulator is for a regimen based on BTK inhibitor Imbruvica (ibrutinib) and Roche’s anti-CD20 drug Gazyva (obinutuzumab) in CLL – the most common form of leukaemia – as well as a related disease called small lymphocytic lymphoma (SLL). The approval is based on the results of the phase III iLLUMINATE study – presented at the American Society of Haematology (ASH) meeting in December .
Read more...